Dare Bioscience

Dare Bioscience Net Debt per Share

The Net Debt per Share of Dare Bioscience (DARE) as of Oct 31, 2026 is -1.54 USD. In the previous year, Net Debt per Share was -1.01 USD — a change of 53.21% (lower).

Net Debt per Share

-1.54USD

YoY

53.21%

Last updated:

Net Debt per Share of Dare Bioscience is 2025 -1.54 USD. Net Debt per Share of Dare Bioscience was 2024 -1.01 USD. It decreases by 53.21% lower compared to the previous year.

The Dare Bioscience Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2017
-0.53 USD
Jan 1, 2019
-0.28 USD
Jan 1, 2020
-0.27 USD
Jan 1, 2021
-3.60 USD
Jan 1, 2022
-2.39 USD
Jan 1, 2023
-0.63 USD
Jan 1, 2024
-1.01 USD
Jan 1, 2025
-1.54 USD
The Dare Bioscience Net Debt per Share history
YEARNet Debt per ShareYoY
-1.54USD+53.21%
-1.01USD+58.68%
-0.63USD-73.46%
-2.39USD-33.50%
-3.60USD+1,213.79%
-0.27USD-1.68%
-0.28USD-47.36%
-0.53USD-65.84%
-1.55USD-60.19%
-3.89USD+15.68%
-3.36USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Net Debt per Share of Dare Bioscience is -1.54 USD in 2025.

Net Debt per Share of Dare Bioscience changed from -1.01 USD to -1.54 USD, representing a 53.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Dare Bioscience

All Key Metrics — Dare Bioscience